180 Life Sciences (ATNF) Competitors $1.03 0.00 (0.00%) Closing price 03/28/2025 03:59 PM EasternExtended Trading$1.03 0.00 (0.00%) As of 03/28/2025 06:55 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock ATNF vs. AFMD, MRKR, SPRB, MTVA, HCWB, IPA, CTXR, ATHA, GOVX, and BMRAShould you be buying 180 Life Sciences stock or one of its competitors? The main competitors of 180 Life Sciences include Affimed (AFMD), Marker Therapeutics (MRKR), Spruce Biosciences (SPRB), MetaVia (MTVA), HCW Biologics (HCWB), ImmunoPrecise Antibodies (IPA), Citius Pharmaceuticals (CTXR), Athira Pharma (ATHA), GeoVax Labs (GOVX), and Biomerica (BMRA). These companies are all part of the "pharmaceutical products" industry. 180 Life Sciences vs. Affimed Marker Therapeutics Spruce Biosciences MetaVia HCW Biologics ImmunoPrecise Antibodies Citius Pharmaceuticals Athira Pharma GeoVax Labs Biomerica Affimed (NASDAQ:AFMD) and 180 Life Sciences (NASDAQ:ATNF) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, earnings, valuation, media sentiment, risk, analyst recommendations, profitability, institutional ownership and community ranking. Do institutionals and insiders believe in AFMD or ATNF? 30.8% of Affimed shares are owned by institutional investors. Comparatively, 4.1% of 180 Life Sciences shares are owned by institutional investors. 3.8% of Affimed shares are owned by insiders. Comparatively, 0.2% of 180 Life Sciences shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term. Does the media prefer AFMD or ATNF? In the previous week, 180 Life Sciences had 1 more articles in the media than Affimed. MarketBeat recorded 5 mentions for 180 Life Sciences and 4 mentions for Affimed. Affimed's average media sentiment score of 0.90 beat 180 Life Sciences' score of 0.37 indicating that Affimed is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Affimed 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive 180 Life Sciences 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Does the MarketBeat Community believe in AFMD or ATNF? Affimed received 437 more outperform votes than 180 Life Sciences when rated by MarketBeat users. Likewise, 70.24% of users gave Affimed an outperform vote while only 22.22% of users gave 180 Life Sciences an outperform vote. CompanyUnderperformOutperformAffimedOutperform Votes43970.24% Underperform Votes18629.76% 180 Life SciencesOutperform Votes222.22% Underperform Votes777.78% Is AFMD or ATNF more profitable? 180 Life Sciences has a net margin of 0.00% compared to Affimed's net margin of -7,836.26%. Affimed's return on equity of -193.84% beat 180 Life Sciences' return on equity.Company Net Margins Return on Equity Return on Assets Affimed-7,836.26% -193.84% -107.24% 180 Life Sciences N/A -558.93%-54.10% Which has more risk and volatility, AFMD or ATNF? Affimed has a beta of 2.22, meaning that its stock price is 122% more volatile than the S&P 500. Comparatively, 180 Life Sciences has a beta of 0.2, meaning that its stock price is 80% less volatile than the S&P 500. Which has higher earnings and valuation, AFMD or ATNF? 180 Life Sciences has lower revenue, but higher earnings than Affimed. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAffimed$877K14.34-$114.66MN/AN/A180 Life SciencesN/AN/A-$19.93MN/AN/A Do analysts prefer AFMD or ATNF? Affimed currently has a consensus target price of $13.50, suggesting a potential upside of 1,628.33%. Given Affimed's stronger consensus rating and higher possible upside, research analysts plainly believe Affimed is more favorable than 180 Life Sciences.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Affimed 0 Sell rating(s) 1 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 2.80180 Life Sciences 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 SummaryAffimed beats 180 Life Sciences on 11 of the 15 factors compared between the two stocks. Remove Ads Get 180 Life Sciences News Delivered to You Automatically Sign up to receive the latest news and ratings for ATNF and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ATNF vs. The Competition Export to ExcelMetric180 Life SciencesPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$3.27M$6.90B$5.63B$7.84BDividend YieldN/A2.77%5.33%4.01%P/E RatioN/A7.2623.6018.74Price / SalesN/A218.62388.2390.77Price / CashN/A65.6738.1734.64Price / Book-4.296.386.894.23Net Income-$19.93M$142.34M$3.20B$247.47M7 Day Performance-8.85%-5.15%-3.06%-2.29%1 Month Performance-11.97%-7.55%1.52%-5.81%1 Year Performance-55.79%-11.06%9.37%-0.96% 180 Life Sciences Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ATNF180 Life SciencesN/A$1.03flatN/A-55.8%$3.27MN/A0.007Short Interest ↑News CoverageAFMDAffimed4.35 of 5 stars$0.87-1.8%$13.50+1,448.2%-85.3%$14.04M$877,000.000.00200Short Interest ↓MRKRMarker Therapeutics3.9363 of 5 stars$1.28+2.4%$13.50+954.7%-70.5%$13.71M$3.31M0.0060Gap UpSPRBSpruce Biosciences3.183 of 5 stars$0.33-2.0%$2.50+657.8%-62.5%$13.63M$7.10M-0.3520Upcoming EarningsShort Interest ↓Positive NewsGap DownMTVAMetaVia2.1819 of 5 stars$1.58+1.9%$12.00+659.5%N/A$13.61MN/A0.0010HCWBHCW Biologics1.4215 of 5 stars$0.30-1.2%N/A-82.9%$13.36M$3.50M-0.3040Earnings ReportUpcoming EarningsGap UpIPAImmunoPrecise Antibodies2.2768 of 5 stars$0.43+1.6%$5.00+1,062.8%-74.2%$13.36M$24.07M-0.5580Earnings ReportShort Interest ↑CTXRCitius Pharmaceuticals3.289 of 5 stars$1.55+2.0%$54.50+3,416.1%-93.1%$13.32MN/A0.0020Positive NewsATHAAthira Pharma2.5127 of 5 stars$0.34+2.4%$13.83+3,968.6%-88.9%$13.27MN/A-0.1240Positive NewsGOVXGeoVax Labs3.0256 of 5 stars$1.40+6.9%$14.20+914.3%-44.5%$13.21M$3.09M0.0010Earnings ReportAnalyst ForecastShort Interest ↓Analyst RevisionNews CoverageBMRABiomerica0.9643 of 5 stars$0.71+3.6%N/A-30.1%$13.02M$5.58M-2.0960Short Interest ↓News CoveragePositive News Remove Ads Related Companies and Tools Related Companies AFMD Competitors MRKR Competitors SPRB Competitors MTVA Competitors HCWB Competitors IPA Competitors CTXR Competitors ATHA Competitors GOVX Competitors BMRA Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ATNF) was last updated on 3/31/2025 by MarketBeat.com Staff From Our PartnersA market crash is coming—here’s whenThe stock market cycle I've used to identify the most likely day of the next market crash is the exact same in...Chaikin Analytics | SponsoredYour Wealth is Under AttackPlease don't wait—this is your moment to take action. Download your Wealth Protection Guide now, claim your fr...American Alternative | SponsoredA brutally honest economic warning for 2025 (see proof)New York Times best-selling financial author and world-renowned economist Addison Wiggin (a man who’s worked s...Banyan Hill Publishing | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredDOGE could send 6 AI stocks through the roofStay alert for Elon Musk and the Department of Government Efficiency's next move … Expect an announcement f...Weiss Ratings | SponsoredURGENT: Someone's Moving Gold Out of London...People who don’t understand the gold market are about to lose a lot of money. Unfortunately, most so-called “g...Golden Portfolio | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredHas Trump finally met his match?Dylan Jovine predicted the 2008 crash over a year before it happened. Folks who listened to him had the chance...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding 180 Life Sciences Corp. Please log in to your account or sign up in order to add this asset to your watchlist. Share 180 Life Sciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy ATNF Stock Free ATNF Stock Alerts